Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 26;28(1):542.
doi: 10.1186/s40001-023-01531-7.

A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports

Affiliations

A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports

Mona Sadat Larijani et al. Eur J Med Res. .

Abstract

There have been massive studies to develop an effective vaccine against SARS-CoV-2 which fortunately led to manage the recent pandemic, COVID-19. According to the quite rapidly developed vaccines in a fast window time, large investigations to assess the probable vaccine-related adverse events are crucially required. COVID-19 vaccines are available of different platforms and the primary clinical trials results presented acceptable safety profile of the approved vaccines. Nevertheless, the long-term assessment of the adverse events or rare conditions need to be investigated. The present systematic review, aimed at classification of probable vaccine-related unsolicited adverse events in Iranian population through the data collection of the published case report studies.The related published case reports were explored via PubMed, Web of Science and Google scholar according to the available published data up to 14th Dec, 2022 using PRISMA guideline. Out of 437 explored studies, the relevant data were fully investigated which totally led to 40 studies, including 64 case reports with a new onset of a problem post-vaccination. The cases were then classified according to the various items, such as the type of adverse event and COVID-19 vaccines.The reported COVID-19 vaccines in the studied cases included BBIBP-CorV, ChAdOx1-S, Sputnik V and COVAXIN. The results showed that the adverse events presented in 8 different categories, including cutaneous involvements in 43.7% (n = 28), neurologic problems (n = 16), blood/vessel involvement (n = 6), cardiovascular involvement (n = 5), ocular disorders (n = 4), liver disorder/failure (n = 2), graft rejection (n = 2) and one metabolic disorder. Notably, almost 60% of the cases had no comorbidities. Moreover, the obtained data revealed nearly half of the incidences occurred after the first dose of injection and the median duration of improvement after the symptom was 10 days (range: 2-120). In addition, 73% of all the cases were either significantly improved or fully recovered. Liver failure following ChAdOx1-S vaccination was the most serious vaccine adverse event which led to death in two individuals with no related medical history.Although the advantages of COVID-19 vaccination is undoubtedly significant, individuals including with a history of serious disease, comorbidities and immunodeficiency conditions should be vaccinated with the utmost caution. This study provides a comprehensive overview and clinical implications of possible vaccine-related adverse events which should be considered in further vaccination strategies. Nevertheless, there might be a bias regarding potential under-reporting and missing data of the case reports included in the present study. Although the reported data are not proven to be the direct vaccination outcomes and could be a possible immune response over stimulation, the people the population with a medium/high risk should be monitored after getting vaccinated against COVID-19 of any platforms. This could be achieved by a carefull attention to the subjects ' medical history and also through consulting with healthcare providers before vaccination.

Keywords: Adverse event; Organ involvement; SARS-CoV-2; Vaccine monitoring.

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to be declared.

Figures

Fig. 1
Fig. 1
The review flowchart based on PRISMA
Fig. 2
Fig. 2
COVID-19 vaccines and their potential association with disorders in case reports. Each complication is shown with a different color to simplify comparison between the vaccines. The final reported status for each disorder is also presented

References

    1. Fotouhi F, Salehi-Vaziri M, Farahmand B, Mostafavi E, Pouriayevali MH, Jalali T, et al. Prolonged viral shedding and antibody persistence in patients with COVID-19. Microbes Infect. 2021 doi: 10.1016/j.micinf.2021.104810. - DOI - PMC - PubMed
    1. Mostafa Salehi-Vaziri TJ, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali MH, Larijani MS, Afzali N, Ramezani A. Clinical Characteristics of SARS-CoV-2 by Re-infection Vs. reactivation: a case series from Iran. Eur J Clin Microbiol Infect Dis. 2021 doi: 10.1007/s10096-021-04221-6. - DOI - PMC - PubMed
    1. Larijani MS, Sadat SM, Bolhassani A, Khodaie A, Pouriayevali MH, Ramezani A. HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c. Curr Drug Delivery. 2020 doi: 10.2174/1567201818666210101113601. - DOI - PubMed
    1. Larijani MS, Ramezani A, Shirazi MMA, Bolhassani A, Pouriayevali MH, Shahbazi S, et al. Evaluation of transduced dendritic cells expressing HIV-1 p24-Nef antigens in HIV-specific cytotoxic T cells induction as a therapeutic candidate vaccine. Virus Res. 2021 doi: 10.1016/j.virusres.2021.198403. - DOI - PubMed
    1. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. New Engl J Med. 2020 doi: 10.1056/NEJMp2005630. - DOI - PubMed

Publication types